Skip to main content
NCBI home page
Clinical and Diagnostic Laboratory Immunology logoLink to Clinical and Diagnostic Laboratory Immunology
. 1994 Nov;1(6):626–632. doi: 10.1128/cdli.1.6.626-632.1994

Human antibody response to the B oligomer of pertussis toxin.

F Lynn 1, W N Burnette 1, G R Siber 1, J L Arciniega 1
PMCID: PMC368377  PMID: 8556512

Abstract

To determine whether antibodies to the B oligomer of pertussis toxin (PT) were present in patients diagnosed with pertussis or vaccinees who had received diphtheria-tetanus-whole-cell pertussis vaccine, we analyzed serum samples from 5 patients and 10 vaccinees by both enzyme-linked immunosorbent assay (ELISA) and Western immunoblotting techniques. Antibodies to the B oligomer were detected by ELISA in all samples containing antibodies to holotoxin. Western immunoblotting procedures were less efficient than ELISA techniques for detecting antibodies to the B oligomer. Antibodies which inhibit the ability of the B oligomer to agglutinate erythrocytes were detected in purified human immunoglobulin preparations. In addition, serum samples containing antibodies to PT inhibited the binding of purified B oligomer and holotoxin to a 165-kDa glycoprotein which has been considered a potential PT receptor in Chinese hamster ovary (CHO) cells. These results suggest that antibodies to the B oligomer contribute to the human serologic response to PT, but their detection and characterization require appropriate methods.

Full text

PDF
626

Images in this article

628Image
on p.628
629Image
on p.629
629Image
on p.629
630Image
on p.630
630Image
on p.630

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arciniega J. L., Burns D. L., Garcia-Ortigoza E., Manclark C. R. Immune response to the B oligomer of pertussis toxin. Infect Immun. 1987 May;55(5):1132–1136. doi: 10.1128/iai.55.5.1132-1136.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Askelöf P., Gillenius P. Effect of lymphocytosis-promoting factor from Bordetella pertussis on cerebellar cyclic GMP levels. Infect Immun. 1982 Jun;36(3):958–961. doi: 10.1128/iai.36.3.958-961.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brennan M. J., David J. L., Kenimer J. G., Manclark C. R. Lectin-like binding of pertussis toxin to a 165-kilodalton Chinese hamster ovary cell glycoprotein. J Biol Chem. 1988 Apr 5;263(10):4895–4899. [PubMed] [Google Scholar]
  4. Burnette W. N. "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate--polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem. 1981 Apr;112(2):195–203. doi: 10.1016/0003-2697(81)90281-5. [DOI] [PubMed] [Google Scholar]
  5. Burnette W. N., Arciniega J. L., Mar V. L., Burns D. L. Properties of pertussis toxin B oligomer assembled in vitro from recombinant polypeptides produced by Escherichia coli. Infect Immun. 1992 Jun;60(6):2252–2256. doi: 10.1128/iai.60.6.2252-2256.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Burns D. L., Hausman S. Z., Lindner W., Robey F. A., Manclark C. R. Structural characterization of pertussis toxin A subunit. J Biol Chem. 1987 Dec 25;262(36):17677–17682. [PubMed] [Google Scholar]
  7. Burns D. L., Kenimer J. G., Manclark C. R. Role of the A subunit of pertussis toxin in alteration of Chinese hamster ovary cell morphology. Infect Immun. 1987 Jan;55(1):24–28. doi: 10.1128/iai.55.1.24-28.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. De Magistris M. T., Romano M., Bartoloni A., Rappuoli R., Tagliabue A. Human T cell clones define S1 subunit as the most immunogenic moiety of pertussis toxin and determine its epitope map. J Exp Med. 1989 May 1;169(5):1519–1532. doi: 10.1084/jem.169.5.1519. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Edwards K. M. Acellular pertussis vaccines--a solution to the pertussis problem? J Infect Dis. 1993 Jul;168(1):15–20. doi: 10.1093/infdis/168.1.15. [DOI] [PubMed] [Google Scholar]
  10. Edwards K. M., Decker M. D., Halsey N. A., Koblin B. A., Townsend T., Auerbach B., Karzon D. T. Differences in antibody response to whole-cell pertussis vaccines. Pediatrics. 1991 Nov;88(5):1019–1023. [PubMed] [Google Scholar]
  11. Englund J. A., Decker M. D., Edwards K. M., Pichichero M. E., Steinhoff M. C., Anderson E. L. Acellular and whole-cell pertussis vaccines as booster doses: a multicenter study. Pediatrics. 1994 Jan;93(1):37–43. [PubMed] [Google Scholar]
  12. Gómez A. M., Rhodes J. C., Deepe G. S., Jr Antigenicity and immunogenicity of an extract from the cell wall and cell membrane of Histoplasma capsulatum yeast cells. Infect Immun. 1991 Jan;59(1):330–336. doi: 10.1128/iai.59.1.330-336.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Irons L. I., MacLennan A. P. Isolation of the lymphocytosis promoting factor-haemagglutinin of Bordetella pertussis by affinity chromatography. Biochim Biophys Acta. 1979 Sep 29;580(1):175–185. doi: 10.1016/0005-2795(79)90208-3. [DOI] [PubMed] [Google Scholar]
  14. Katada T., Tamura M., Ui M. The A protomer of islet-activating protein, pertussis toxin, as an active peptide catalyzing ADP-ribosylation of a membrane protein. Arch Biochem Biophys. 1983 Jul 1;224(1):290–298. doi: 10.1016/0003-9861(83)90212-6. [DOI] [PubMed] [Google Scholar]
  15. Katada T., Ui M. Direct modification of the membrane adenylate cyclase system by islet-activating protein due to ADP-ribosylation of a membrane protein. Proc Natl Acad Sci U S A. 1982 May;79(10):3129–3133. doi: 10.1073/pnas.79.10.3129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kenimer J. G., Kim K. J., Probst P. G., Manclark C. R., Burstyn D. G., Cowell J. L. Monoclonal antibodies to pertussis toxin: utilization as probes of toxin function. Hybridoma. 1989 Feb;8(1):37–51. doi: 10.1089/hyb.1989.8.37. [DOI] [PubMed] [Google Scholar]
  17. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  18. Lang A. B., Ganss M. T., Cryz S. J., Jr Monoclonal antibodies that define neutralizing epitopes of pertussis toxin: conformational dependence and epitope mapping. Infect Immun. 1989 Sep;57(9):2660–2665. doi: 10.1128/iai.57.9.2660-2665.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Lobet Y., Feron C., Dequesne G., Simoen E., Hauser P., Locht C. Site-specific alterations in the B oligomer that affect receptor-binding activities and mitogenicity of pertussis toxin. J Exp Med. 1993 Jan 1;177(1):79–87. doi: 10.1084/jem.177.1.79. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Loosmore S., Zealey G., Cockle S., Boux H., Chong P., Yacoob R., Klein M. Characterization of pertussis toxin analogs containing mutations in B-oligomer subunits. Infect Immun. 1993 Jun;61(6):2316–2324. doi: 10.1128/iai.61.6.2316-2324.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Nogimori K., Tamura M., Yajima M., Ito K., Nakamura T., Kajikawa N., Maruyama Y., Ui M. Dual mechanisms involved in development of diverse biological activities of islet-activating protein, pertussis toxin, as revealed by chemical modification of lysine residues in the toxin molecule. Biochim Biophys Acta. 1984 Sep 28;801(2):232–243. doi: 10.1016/0304-4165(84)90072-2. [DOI] [PubMed] [Google Scholar]
  22. Petersen J. W., Holm A., Ibsen P. H., Hasløv K., Capiau C., Heron I. Identification of human T-cell epitopes on the S4 subunit of pertussis toxin. Infect Immun. 1992 Oct;60(10):3962–3970. doi: 10.1128/iai.60.10.3962-3970.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Sato H., Ito A., Chiba J., Sato Y. Monoclonal antibody against pertussis toxin: effect on toxin activity and pertussis infections. Infect Immun. 1984 Nov;46(2):422–428. doi: 10.1128/iai.46.2.422-428.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Sato Y., Cowell J. L., Sato H., Burstyn D. G., Manclark C. R. Separation and purification of the hemagglutinins from Bordetella pertussis. Infect Immun. 1983 Jul;41(1):313–320. doi: 10.1128/iai.41.1.313-320.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Stein P. E., Boodhoo A., Armstrong G. D., Cockle S. A., Klein M. H., Read R. J. The crystal structure of pertussis toxin. Structure. 1994 Jan 15;2(1):45–57. doi: 10.1016/s0969-2126(00)00007-1. [DOI] [PubMed] [Google Scholar]
  26. Tamura M., Nogimori K., Murai S., Yajima M., Ito K., Katada T., Ui M., Ishii S. Subunit structure of islet-activating protein, pertussis toxin, in conformity with the A-B model. Biochemistry. 1982 Oct 26;21(22):5516–5522. doi: 10.1021/bi00265a021. [DOI] [PubMed] [Google Scholar]
  27. Tamura M., Nogimori K., Yajima M., Ase K., Ui M. A role of the B-oligomer moiety of islet-activating protein, pertussis toxin, in development of the biological effects on intact cells. J Biol Chem. 1983 Jun 10;258(11):6756–6761. [PubMed] [Google Scholar]
  28. Thomas M. G., Redhead K., Lambert H. P. Human serum antibody responses to Bordetella pertussis infection and pertussis vaccination. J Infect Dis. 1989 Feb;159(2):211–218. doi: 10.1093/infdis/159.2.211. [DOI] [PubMed] [Google Scholar]
  29. Zaccolo M., Roggero S., Armellini D., Pegoraro L., Rappuoli R., Malavasi F. Generation of human monoclonal antibodies that confer protection against pertussis toxin. Infect Immun. 1992 Mar;60(3):1258–1260. doi: 10.1128/iai.60.3.1258-1260.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Diagnostic Laboratory Immunology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES